NF-κB-regulated VentX Expression Mediates Tumoricidal Effects of Chemotherapeutics at Noncytotoxic Concentrations

Overview

Journal iScience

Publisher Cell Press

Date 2022 Nov 17

PMID 36388981

Authors

Yi Le

Hong Gao

Angie Zhu

Kristen Felt

Scott Rodig

Ronald Bleday

Zhenglun Zhu

Affiliations

Soon will be listed here.

Abstract

Limited therapeutic efficacy and severe side effects represent the central hurdles facing cancer chemotherapy. Immune suppression within tumor immune microenvironments (TIME) has been implicated in chemoresistance. In this study, using a TIME-enabling model system (TIME-EMS), we demonstrate that the chemotherapeutic agent doxorubicin has cytocidal effects on tumor cells at high dosage but induces changes in the immune landscape of the TIME at low noncytotoxic concentrations via NF-κB-mediated induction of homeobox protein VentX expression in tumor-associated macrophages (TAMs). We demonstrated that VentX-regulated TAMs drastically promote tumor chemosensitivity >10-fold but exert little effect on chemotoxicity to normal cells through activating cytotoxic T lymphocytes in a tumor-specific manner. Supported by the synergy of VentX-regulated TAMs and low-dosage noncytotoxic doxorubicin, our data suggest a cell-death-independent immune mechanism for improving the therapeutic index of chemotherapeutic agents.

Citing Articles

VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors.

Le Y, Gao H, Le J, Hornick J, Bleday R, Wee J iScience. 2024; 27(1):108731.

PMID: 38299030 PMC: 10829883. DOI: 10.1016/j.isci.2023.108731.

References

Biswas S, Lewis C . NF-κB as a central regulator of macrophage function in tumors. J Leukoc Biol. 2010; 88(5):877-84. DOI: 10.1189/jlb.0310153. View

Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T . Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med. 2009; 48(4):203-8. DOI: 10.2169/internalmedicine.48.1659. View

Wu X, Gao H, Ke W, Giese R, Zhu Z . The homeobox transcription factor VentX controls human macrophage terminal differentiation and proinflammatory activation. J Clin Invest. 2011; 121(7):2599-613. PMC: 3223833. DOI: 10.1172/JCI45556. View

de Palma M, Lewis C . Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013; 23(3):277-86. DOI: 10.1016/j.ccr.2013.02.013. View

Wu X, Gao H, Bleday R, Zhu Z . Homeobox transcription factor VentX regulates differentiation and maturation of human dendritic cells. J Biol Chem. 2014; 289(21):14633-43. PMC: 4031519. DOI: 10.1074/jbc.M113.509158. View

Ben-Neriah Y, Karin M . Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011; 12(8):715-23. DOI: 10.1038/ni.2060. View

Freeman A, Hoffman R . In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci U S A. 1986; 83(8):2694-8. PMC: 323366. DOI: 10.1073/pnas.83.8.2694. View

Gao H, Wu B, Giese R, Zhu Z . Xom interacts with and stimulates transcriptional activity of LEF1/TCFs: implications for ventral cell fate determination during vertebrate embryogenesis. Cell Res. 2007; 17(4):345-56. DOI: 10.1038/cr.2007.20. View

Noy R, Pollard J . Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41(1):49-61. PMC: 4137410. DOI: 10.1016/j.immuni.2014.06.010. View

10.

Bracci L, Schiavoni G, Sistigu A, Belardelli F . Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2013; 21(1):15-25. PMC: 3857622. DOI: 10.1038/cdd.2013.67. View

11.

Arlt A, Vorndamm J, Breitenbroich M, Folsch U, Kalthoff H, Schmidt W . Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 2001; 20(7):859-68. DOI: 10.1038/sj.onc.1204168. View

12.

Solimini N, Luo J, Elledge S . Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007; 130(6):986-8. DOI: 10.1016/j.cell.2007.09.007. View

13.

Podyacheva E, Kushnareva E, Karpov A, Toropova Y . Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician. Front Pharmacol. 2021; 12:670479. PMC: 8209419. DOI: 10.3389/fphar.2021.670479. View

14.

Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B . Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J. 2002; 367(Pt 3):729-40. PMC: 1222928. DOI: 10.1042/BJ20020752. View

15.

Mantovani A, Polentarutti N, Luini W, Peri G, Spreafico F . Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice. J Natl Cancer Inst. 1979; 63(1):61-6. View

16.

Carey C, Gusenleitner D, Lipschitz M, Roemer M, Stack E, Gjini E . Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017; 130(22):2420-2430. PMC: 5766840. DOI: 10.1182/blood-2017-03-770719. View

17.

Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T . Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008; 118(6):2269-80. PMC: 2391067. DOI: 10.1172/JCI34610. View

18.

Gao H, Le Y, Wu X, Silberstein L, Giese R, Zhu Z . VentX, a novel lymphoid-enhancing factor/T-cell factor-associated transcription repressor, is a putative tumor suppressor. Cancer Res. 2009; 70(1):202-11. DOI: 10.1158/0008-5472.CAN-09-2668. View

19.

Rogler G, Hausmann M, Vogl D, Aschenbrenner E, Andus T, Falk W . Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol. 1998; 112(2):205-15. PMC: 1904962. DOI: 10.1046/j.1365-2249.1998.00557.x. View

20.

DeVita Jr V, Chu E . A history of cancer chemotherapy. Cancer Res. 2008; 68(21):8643-53. DOI: 10.1158/0008-5472.CAN-07-6611. View